Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Apollo Global Management Ord Shs (APO) vs Merck & Co., Inc. (MRK) Price & Performance

Apollo Global Management Ord ShsTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Apollo Global Management Ord Shs vs Merck & Co., Inc. — how do they compare? Apollo Global Management Ord Shs trades at $140.5 (market cap $76.04B), while Merck & Co., Inc. trades at $130.11 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 4.2× Apollo Global Management Ord Shs's market cap, and Merck & Co., Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.

APOMRK
Market Cap
$76.04B$323.00B
Sector
FinancialsHealth
52-Week High
$152.70$131.84
52-Week Low
$100.30$77.60
Enterprise Value
-$175.45B$369.77B
Dividend Yield
1.7%2.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Apollo Global Management Ord Shs

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.

The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Apollo Global Management Ord Shs

Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit

Read more on APO

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK